SPOTLIGHT: Avandia cleared FDA by one vote

SPOTLIGHT ... Avandia cleared FDA by one vote
Behind closed doors, the FDA's safety board barely backed GlaxoSmithKline's Avandia last month, voting 8-to-7 to keep the drug on the market with tougher warnings of heart risks rather than pull it completely. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.